<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Active <z:e sem="disease" ids="C0010481" disease_type="Disease or Syndrome" abbrv="">Cushing's syndrome</z:e> (CS) is associated with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, characterized by myocardial structural, and ultrastructural abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>The extent of <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> in patients with CS has not been previously evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the objective of this study was to assess <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> in CS patients, its relationship with left ventricular (LV) <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> and function, and its reversibility after surgical treatment </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN AND METHODS: Fifteen consecutive CS patients (41±12 years) were studied together with 30 hypertensive (HT) patients (matched for LV <z:mpath ids='MPATH_159'>hypertrophy</z:mpath>) and 30 healthy subjects </plain></SENT>
<SENT sid="4" pm="."><plain>Echocardiography was performed in <z:hpo ids='HP_0000001'>all</z:hpo> patients including i) LV systolic function assessment by conventional measures and by speckle tracking-derived global longitudinal strain, ii) LV diastolic function assessment using E/E', and iii) <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> assessment using calibrated integrated backscatter (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Echocardiography was repeated after normalization of <z:chebi fb="1" ids="17650">cortisol</z:chebi> secretion (14±3 months) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: CS patients showed the highest value of calibrated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> (-15.1±2.5  dB) compared with HT patients (-20.0±2.6  dB, P&lt;0.01) and controls (-23.8±2.4  dB, P&lt;0.01), indicating increased <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> independent of LV <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, calibrated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> in CS patients was significantly related to both diastolic function (E/E', r=0.79, P&lt;0.01) and systolic function (global longitudinal strain, r=0.60, P=0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>After successful surgical treatment, calibrated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> normalized (-21.0±3.8 vs -15.1±2.5  dB, P&lt;0.01), suggestive of regression of <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Patients with CS have increased <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo>, which is related to LV systolic and diastolic dysfunction </plain></SENT>
<SENT sid="10" pm="."><plain>Successful treatment of CS normalizes the extent of <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> appears to be an important factor in the development and potential regression of CS <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>